CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma

@inproceedings{Chu2014CS1SpecificCA,
  title={CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma},
  author={Jianhong Chu and Youcai Deng and Don Michael Benson and Shun He and Tiffany Hughes and Jianying Zhang and Yong Peng and Hsiaoyin Charlene Mao and Ling Yi and Kalpana Ghoshal and Xiaoming He and Steven Michael Devine and Xiaoliu Zhang and Michael A. Caligiuri and Craig C Hofmeister and Jianhua Yu},
  booktitle={Leukemia},
  year={2014}
}
Multiple myeloma (MM) is an incurable hematological malignancy. Chimeric antigen receptor (CAR)-expressing T cells have been demonstrated successfully in the clinic to treat B-lymphoid malignancies. However, the potential utility of antigen-specific CAR-engineered natural-killer (NK) cells to treat MM has not been explored. In this study, we determined whether CS1, a surface protein that is highly expressed on MM cells, can be targeted by CAR NK cells to treat MM. We successfully generated a… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 13 times over the past 90 days. VIEW TWEETS
84 Citations
58 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 84 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 58 references

New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients

  • NW vandeDonk, HM Lokhorst
  • Expert Opin Pharmacother
  • 2013

Similar Papers

Loading similar papers…